French clinical-stage biotechnology company Therachon announced it has completed a $60 million mezzanine financing.

The round was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures, and funds managed by Tekla Capital Management LLC.

Existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative also participated.

Therachon plans to use the proceeds to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia.